|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LGALSL |
Gene summary for LGALSL |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LGALSL | Gene ID | 29094 |
| Gene name | galectin like | |
| Gene Alias | GRP | |
| Cytomap | 2p14 | |
| Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | Q3ZCW2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 29094 | LGALSL | LZE4T | Human | Esophagus | ESCC | 1.59e-03 | 9.66e-02 | 0.0811 |
| 29094 | LGALSL | LZE7T | Human | Esophagus | ESCC | 8.82e-03 | 3.50e-01 | 0.0667 |
| 29094 | LGALSL | LZE24T | Human | Esophagus | ESCC | 4.57e-04 | 6.06e-02 | 0.0596 |
| 29094 | LGALSL | P1T-E | Human | Esophagus | ESCC | 7.28e-03 | 3.02e-01 | 0.0875 |
| 29094 | LGALSL | P2T-E | Human | Esophagus | ESCC | 1.19e-23 | 4.21e-01 | 0.1177 |
| 29094 | LGALSL | P4T-E | Human | Esophagus | ESCC | 4.82e-18 | 7.07e-01 | 0.1323 |
| 29094 | LGALSL | P5T-E | Human | Esophagus | ESCC | 2.47e-13 | 3.89e-01 | 0.1327 |
| 29094 | LGALSL | P8T-E | Human | Esophagus | ESCC | 2.18e-18 | 4.34e-01 | 0.0889 |
| 29094 | LGALSL | P9T-E | Human | Esophagus | ESCC | 1.08e-09 | 4.36e-01 | 0.1131 |
| 29094 | LGALSL | P10T-E | Human | Esophagus | ESCC | 1.55e-14 | 1.99e-01 | 0.116 |
| 29094 | LGALSL | P11T-E | Human | Esophagus | ESCC | 9.09e-06 | 4.42e-01 | 0.1426 |
| 29094 | LGALSL | P12T-E | Human | Esophagus | ESCC | 1.17e-26 | 5.44e-01 | 0.1122 |
| 29094 | LGALSL | P15T-E | Human | Esophagus | ESCC | 1.90e-12 | 3.43e-01 | 0.1149 |
| 29094 | LGALSL | P16T-E | Human | Esophagus | ESCC | 5.89e-27 | 4.11e-01 | 0.1153 |
| 29094 | LGALSL | P20T-E | Human | Esophagus | ESCC | 7.69e-15 | 2.56e-01 | 0.1124 |
| 29094 | LGALSL | P21T-E | Human | Esophagus | ESCC | 1.42e-18 | 2.58e-01 | 0.1617 |
| 29094 | LGALSL | P22T-E | Human | Esophagus | ESCC | 2.81e-23 | 1.80e-01 | 0.1236 |
| 29094 | LGALSL | P23T-E | Human | Esophagus | ESCC | 5.75e-12 | 3.83e-01 | 0.108 |
| 29094 | LGALSL | P24T-E | Human | Esophagus | ESCC | 9.50e-19 | 6.65e-02 | 0.1287 |
| 29094 | LGALSL | P26T-E | Human | Esophagus | ESCC | 4.69e-36 | 5.86e-01 | 0.1276 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| LGALSL | SNV | Missense_Mutation | novel | c.88G>A | p.Asp30Asn | p.D30N | Q3ZCW2 | protein_coding | deleterious(0.03) | benign(0.021) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| LGALSL | SNV | Missense_Mutation | c.256G>A | p.Glu86Lys | p.E86K | Q3ZCW2 | protein_coding | tolerated(0.23) | benign(0.062) | TCGA-AN-A0FT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| LGALSL | SNV | Missense_Mutation | novel | c.322N>A | p.Glu108Lys | p.E108K | Q3ZCW2 | protein_coding | tolerated(0.28) | benign(0.028) | TCGA-OL-A6VQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| LGALSL | SNV | Missense_Mutation | rs150631870 | c.458C>T | p.Thr153Met | p.T153M | Q3ZCW2 | protein_coding | deleterious(0.02) | possibly_damaging(0.477) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| LGALSL | SNV | Missense_Mutation | novel | c.242N>G | p.Ala81Gly | p.A81G | Q3ZCW2 | protein_coding | tolerated(0.16) | benign(0.025) | TCGA-AA-A02J-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| LGALSL | SNV | Missense_Mutation | novel | c.199N>G | p.Phe67Val | p.F67V | Q3ZCW2 | protein_coding | deleterious(0) | probably_damaging(0.958) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| LGALSL | SNV | Missense_Mutation | c.256G>A | p.Glu86Lys | p.E86K | Q3ZCW2 | protein_coding | tolerated(0.23) | benign(0.062) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| LGALSL | SNV | Missense_Mutation | c.256N>A | p.Glu86Lys | p.E86K | Q3ZCW2 | protein_coding | tolerated(0.23) | benign(0.062) | TCGA-EO-A3AY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| LGALSL | SNV | Missense_Mutation | rs757537218 | c.443N>G | p.Tyr148Cys | p.Y148C | Q3ZCW2 | protein_coding | tolerated(0.06) | probably_damaging(0.966) | TCGA-EY-A1GD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| LGALSL | SNV | Missense_Mutation | rs779816165 | c.449N>A | p.Arg150His | p.R150H | Q3ZCW2 | protein_coding | deleterious(0) | possibly_damaging(0.884) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |